Cellectis is the pioneering gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells.

Gene editing

The principle of gene editing is very simple: in the same way that spell check identifies and corrects errors in a word or grammar errors in a sentence, gene editing can be used to precisely edit the genetic code within an individual's DNA.
Learn more


Our product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target cancers.
Learn more